Objective: This analysis evaluated the sustained effects of onabotulinumtoxinA in patients with CD who were naive or non-naive to botulinum toxin at enrollment in CD PROBE (CD Patient Registry for Observation of BOTOX® Efficacy), a multi-center, prospective, observational study of up to three onabotulinumtoxinA treatments.

Background: OnabotulinumtoxinA is a level-A treatment for cervical dystonia (CD) due to its proven efficacy and safety.

Method: For this analysis, patients were included if they completed all treatment cycles and had accompanying data. Assessments included CD severity, Cervical Dystonia Impact Profile (CDIP-58), Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), treatment interval, and total dose. Adverse events (AEs) were also recorded.

Results: Changes in severity following each onabotulinumtoxinA treatment were generally similar between naive (n=212) and non-naive (n=138) patients. Severity scores were maintained or improved in most patients with mild to moderate symptoms, while 30.0-66.7% with the highest severity scores shifted to a lower severity score across the three treatments. Similarly, sustained improvements were seen in all CDIP-58 subscales and in TWSTRS total scores irrespective of CD severity and toxin status at baseline. The median time interval between injections was similar in naive (93.0–98.0 days) and non-naive patients (96.0–97.0 days); doses tended to be lower in naïve patients. The most common AEs (dysphagia, muscular weakness) were similar.

Conclusion: CD severity was attenuated by repeat onabotulinumtoxinA treatments at consistent intervals regardless of prior botulinum toxin exposure as seen in this preliminary completer analysis. Treatments were well tolerated.

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/benefits-of-treatment-with-onabotulinumtoxina-in-naive-and-non-naive-patients-with-cervical-dystonia-are-sustained-over-time-preliminary-completer-analysis-from-cd-probe/